This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform
by Zacks Equity Research
Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.
4 Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Sundeep Ganoria
Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in second-quarter 2023, partially offset by lower sales of swine products.
ANI Pharmaceuticals (ANIP) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) second-quarter 2023 performance is likely to have been driven by rising generic and rare disease product revenues.
Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Adaptimmune (ADAP) is expected to provide regulatory and developmental updates on its pipeline programs in its upcoming earnings release, given the absence of marketed products in its portfolio.
ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs.
Amphastar (AMPH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Amphastar's (AMPH) revenues in the second quarter of 2023 are expected to have been driven by the sales of its high-margin pharmaceutical products.
Perrigo (PRGO) Gets FDA Nod for First OTC Birth Control Pill
by Zacks Equity Research
Following the FDA approval, Perrigo's (PRGO) Opill is the first ever over-the-counter birth control pill. The drug will be made available in the United States early next year.
First Wave (FWBI) Down 32% on Cystic Fibrosis Study Setback
by Zacks Equity Research
Initial data from First Wave's (FWBI) mid-stage study evaluating its investigational oral capsule in cystic fibrosis patients did not likely meet its primary endpoint.
Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder
by Zacks Equity Research
If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.
Axsome (AXSM) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Axsome (AXSM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for July 11th
by Zacks Equity Research
AXSM, HIVE and TIMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 11, 2023.
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
by Zacks Equity Research
Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.
Axsome (AXSM) Down on Public Offering of Common Stock
by Zacks Equity Research
Axsome (AXSM) is set to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.
Axsome (AXSM) Soars 8.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises
by Zacks Equity Research
Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of 80.53% and 252.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth
by Zacks Equity Research
Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.
Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe
by Zacks Equity Research
Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
3 Medical Stocks With Solid Growth Potential to Keep Track Of
by Indrajit Bandyopadhyay
Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.
Axsome (AXSM) Down 9.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome (AXSM) Stock Up 17% in Six Months: Here's Why
by Zacks Equity Research
Axsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the addition of Sunosi boosts its top line.